Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022
20 December 2021 - 11:47PM
Business Wire
Event will review the company’s pipeline of
clinical development programs, with a deep dive on NYX-2925 and
chronic pain
Featured presentation by Dr. Richard Rauck,
board certified physician in pain medicine and anesthesiology at
Carolinas Pain Institute and medical director for The Center for
Clinical Research
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that it will
host a virtual portfolio review event on Wednesday, February 9,
2022 from 10:00 a.m. to 11:30 a.m. ET. The live webcast event will
review Aptinyx’s full pipeline of clinical development programs,
with particular focus on NYX-2925, the company’s drug candidate in
development for the treatment of chronic pain.
The program will feature a presentation by Richard Rauck, MD, a
board-certified physician in pain medicine and anesthesiology at
Carolinas Pain Institute and medical director for The Center for
Clinical Research. Dr. Rauck is an investigator in the company’s
ongoing Phase 2b study of NYX-2925 in painful diabetic peripheral
neuropathy (DPN).
The event will also include presentations from the Aptinyx
management team discussing the company’s novel approach to
discovering and developing NMDA receptor modulators, as well as
reviews of each of the company’s clinical development programs.
Aptinyx management will provide a deep-dive review of NYX-2925, the
company’s first-in-class NMDA receptor positive allosteric
modulator in development for the treatment of chronic pain. In
October, Aptinyx announced the completion of enrollment in its
Phase 2b study of NYX-2925 in patients with painful DPN and expects
to report data from the study in the early to mid second quarter of
2022. Aptinyx’s concurrent Phase 2b study of NYX-2925 in patients
with fibromyalgia is expected to report data in mid 2022. The
Aptinyx management team and Dr. Rauck will be available for Q&A
following the presentations.
Video Webcast Information
A live video webcast of the event will be available on the
“Events and Presentations” page in the “Investors & Media”
section of Aptinyx’s website at https://ir.aptinyx.com. A replay of
the webcast will be archived on Aptinyx’s website following the
event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment. Aptinyx is also advancing additional compounds from its
proprietary discovery platform, which continues to generate a rich
and diverse pipeline of small-molecule NMDA receptor modulators
with the potential to treat an array of neurologic disorders. For
more information, visit www.aptinyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the company’s business plans and objectives, including future
plans, expectations, and potential therapeutic effects of its
development candidates, expectations regarding the timing for the
company’s receipt and announcement of data, and expectations
regarding its preclinical development activities. Risks that
contribute to the uncertain nature of the forward-looking
statements include: the effect of COVID-19 on our business and
financial results, including with respect to disruptions to our
clinical trials, business operations, and ability to raise
additional capital; the success, cost, and timing of the company’s
product candidate development activities and planned clinical
studies; the company’s ability to execute on its strategy; that
positive results from a clinical study may not necessarily be
predictive of the results of future or ongoing clinical studies;
regulatory developments in the United States and foreign countries;
the company’s estimates regarding expenses, future revenue, and
capital requirements; as well as those risks and uncertainties set
forth in the company’s most recent annual report on Form 10-K and
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211220005244/en/
Investor & Media Contact: Patrick Flavin Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024